Literature DB >> 10691220

Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief.

C Motamed1, X Mazoit, K Ghanouchi, F Guirimand, K Abhay, T Lieutaud, S Bensaid, C Fernandez, P Duvaldestin.   

Abstract

BACKGROUND: Morphine-6-glucuronide (M-6-G), a major metabolite of morphine, is reported to be more potent than morphine when administered intrathecally; however, its efficiency remains under debate when administered intravenously. This study was designed to assess the analgesic efficiency of intravenous M-6-G for the treatment of acute postoperative pain.
METHODS: After informed consent was obtained, 37 adults (American Society of Anesthesiologists physical status I-II) who were scheduled for elective open knee surgery were enrolled in the study. General anesthesia was induced with thiopental, alfentanil, and vecuronium and was maintained with a mixture of nitrous oxide/isoflurane and bolus doses of alfentanil. At skin closure, patients were randomized into three groups: (1) morphine group (n = 13), which received morphine 0.15 mg/kg; (2) M-6-G group (n = 12), which received M-6-G 0.1 mg/kg; and (3) placebo group (n = 12), which received saline. At the time of extubation, plasma concentration of morphine and M-6-G was measured. Postoperative analgesic efficiency was assessed by the cumulative dose of morphine delivered by patient-controlled analgesia. Opioid-related side effects were also evaluated.
RESULTS: No difference was noted in patient characteristics and opioid-related side effects. Morphine requirements (mean +/- SD) during the first 24 h in the M-6-G group (41+/-9 mg) and the placebo group (49+/-8 mg) were significantly greater (P<0.05) compared with the morphine group (29+/-8 mg).
CONCLUSION: A single intravenous bolus dose of M-6-G was found to be ineffective in the treatment of acute postoperative pain. This might be related to the low permeability of the blood-brain barrier for M-6-G.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691220     DOI: 10.1097/00000542-200002000-00015

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  Role of morphine's metabolites in analgesia: concepts and controversies.

Authors:  Erica Wittwer; Steven E Kern
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

Review 2.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 3.  Morphine-6-glucuronide: an analgesic of the future?

Authors:  J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Developing a vaccine against multiple psychoactive targets: a case study of heroin.

Authors:  G Neilm Stowe; Joel E Schlosburg; Leandro F Vendruscolo; Scott Edwards; Kaushik K Misra; Gery Schulteis; Joseph S Zakhari; George F Koob; Kim D Janda
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

5.  The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.

Authors:  Richard T Penson; Simon P Joel; Michael Roberts; Anna Gloyne; Stephen Beckwith; Maurice L Slevin
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

6.  Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.

Authors:  Ingolf Meineke; Stefan Freudenthaler; Ute Hofmann; Elke Schaeffeler; Gerd Mikus; Matthias Schwab; Hilmar W Prange; Christoph H Gleiter; J Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

7.  Effect of preoperative hydromorphone in patients undergoing laparoscopic radical gastrectomy. A double-blind, randomized and controlled trial.

Authors:  Jinguo Wang; Na Wang; Honglan Zhou; Yuanyuan Wang
Journal:  Saudi Med J       Date:  2018-10       Impact factor: 1.484

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.